Candida bloodstream infections in intensive care units: Analysis of the extended prevalence of infection in intensive care unit study*
暂无分享,去创建一个
Elie Azoulay | J. Vincent | É. Azoulay | Jean-Louis Vincent | D. Kett | P. Echeverria | Daniel H Kett | Pablo M Echeverria
[1] D. Benjamin,et al. Comparison of costs, length of stay, and mortality associated with Candida glabrata and Candida albicans bloodstream infections. , 2010, American journal of infection control.
[2] Jordi Rello,et al. International study of the prevalence and outcomes of infection in intensive care units. , 2009, JAMA.
[3] D. Denning,et al. Excess mortality, length of stay and cost attributable to candidaemia. , 2009, The Journal of infection.
[4] C. O. Kim,et al. Blood Stream Infections by Candida glabrata and Candida krusei: A Single-Center Experience , 2009, The Korean journal of internal medicine.
[5] M. Pfaller,et al. Variation in Susceptibility of Bloodstream Isolates of Candida glabrata to Fluconazole According to Patient Age and Geographic Location in the United States in 2001 to 2007 , 2009, Journal of Clinical Microbiology.
[6] D. Marriott,et al. Determinants of mortality in non-neutropenic ICU patients with candidaemia , 2009, Critical care.
[7] W. Peetermans,et al. Significance of the isolation of Candida species from airway samples in critically ill patients: a prospective, autopsy study , 2009, Intensive Care Medicine.
[8] J. Sobel,et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] J. Vincent,et al. Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care , 1998, Intensive Care Medicine.
[10] A. Kumar. Empirical Fluconazole versus Placebo for Intensive Care Unit Patients: A Randomized Trial , 2009 .
[11] E. Anaissie,et al. Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections. , 2007, Diagnostic microbiology and infectious disease.
[12] M. Pfaller,et al. In Vitro Susceptibility of Invasive Isolates of Candida spp. to Anidulafungin, Caspofungin, and Micafungin: Six Years of Global Surveillance , 2007, Journal of Clinical Microbiology.
[13] R. Betts,et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] K. Laupland,et al. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. , 2007, The Journal of antimicrobial chemotherapy.
[15] R. Betts,et al. Anidulafungin versus fluconazole for invasive candidiasis. , 2007, The New England journal of medicine.
[16] D. Pittet,et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial , 2007, The Lancet.
[17] P. Lipsett,et al. The association between anatomic site of Candida colonizaton, invasive candidiasis, and mortality in critically ill surgical patients: [Diagnostic Microbiology and Infectious Disease 55, 293–301, 2006] , 2007 .
[18] B. Alexander,et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting , 2007, European Journal of Clinical Microbiology & Infectious Diseases.
[19] P. Lipsett,et al. The association between anatomic site of Candida colonization, invasive candidiasis, and mortality in critically ill surgical patients. , 2006, Diagnostic microbiology and infectious disease.
[20] K. Garey,et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[21] M. Falagas,et al. Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies , 2006, European Journal of Clinical Microbiology and Infectious Diseases.
[22] J. Timsit,et al. Excess risk of death from intensive care unit-acquired nosocomial bloodstream infections: a reappraisal. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] J. Garnacho-Montero,et al. A bedside scoring system (“Candida score”) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization* , 2006, Critical care medicine.
[24] D. Denning,et al. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? , 2006, The Journal of antimicrobial chemotherapy.
[25] J. Berlin,et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[26] Victoria J. Fraser,et al. Delaying the Empiric Treatment of Candida Bloodstream Infection until Positive Blood Culture Results Are Obtained: a Potential Risk Factor for Hospital Mortality , 2005, Antimicrobial Agents and Chemotherapy.
[27] Jonathan Cohen,et al. The International Sepsis Forum Consensus Conference on Definitions of Infection in the Intensive Care Unit , 2005, Critical care medicine.
[28] S. Fridkin,et al. Epidemiology and Predictors of Mortality in Cases of Candida Bloodstream Infection: Results from Population-Based Surveillance, Barcelona, Spain, from 2002 to 2003 , 2005, Journal of Clinical Microbiology.
[29] J. Vincent,et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure , 1996, Intensive Care Medicine.
[30] R. Wenzel,et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[31] O. Faure,et al. Epidemiology of Candidaemia in Europe: Results of 28-Month European Confederation of Medical Mycology (ECMM) Hospital-Based Surveillance Study , 2004, European Journal of Clinical Microbiology and Infectious Diseases.
[32] J. Bartlett. Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study , 2004 .
[33] Shane Gillespie,et al. Attributable mortality of nosocomial candidemia, revisited. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[34] W. Powderly,et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[35] J. Perfect,et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. , 2002, The New England journal of medicine.
[36] D. Pittet,et al. Secular Trends of Candidemia Over 12 Years in Adult Patients at a Tertiary Care Hospital , 2002, Medicine.
[37] B. Guidet,et al. Systemic candidiasis in intensive care units: a multicenter, matched-cohort study. , 2002, Journal of critical care.
[38] J. Beney,et al. The direct cost and incidence of systemic fungal infections. , 2002, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[39] K. Giercksky,et al. Yeast Colonization in Surgical Patients with Intra-Abdominal Perforations , 2001, European Journal of Clinical Microbiology and Infectious Diseases.
[40] N. Powe,et al. Candida Infections: Outcome and Attributable ICU Costs in Critically Ill Patients , 2000 .
[41] P. Tambyah,et al. Catheter-associated urinary tract infection is rarely symptomatic: a prospective study of 1,497 catheterized patients. , 2000, Archives of internal medicine.
[42] J. Sobel,et al. Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[43] L. Saiman,et al. National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[44] M. Halpern,et al. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[45] S. Lemeshow,et al. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. , 1993, JAMA.
[46] R. Woolson,et al. Risk factors for hospital-acquired candidemia. A matched case-control study. , 1989, Archives of internal medicine.